Iterum Therapeutics plc Ordinary Share (ITRM)
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing and commercializing innovative antibiotics for serious and life-threatening infections. The company aims to address the growing problem of antibiotic resistance by creating new therapies to treat resistant bacterial infections. Its pipeline includes oral and intravenous formulations designed to combat multidrug-resistant pathogens.
Company News
Iterum Therapeutics reported a Q2 2025 loss of $0.13 per share, higher than expected, as the company prepares for the commercial launch of its oral antibiotic ORLYNVAHâ„¢ for urinary tract infections. The company has secured manufacturing agreements and extended its cash runway into 2026.
Iterum Therapeutics plans to launch ORLYNVAHâ„¢, its first branded antibiotic for uncomplicated urinary tract infections, in August 2025. The company has partnered with EVERSANA for commercialization and has sufficient cash runway into 2026.
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
The Dow Jones index closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insi...
More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.